Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200–500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR study

Brinton, Eliot A; Ballantyne, Christie M; Bays, Harold E; Kastelein, John J; Braeckman, Rene A; Soni, Paresh N

doi:10.1186/1475-2840-12-100

Cardiovascular Diabetology

Table 2 Change in diabetes end points following IPE treatment in diabetes subgroups by median baseline A _1c

From: Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200–500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR study

Parameter	All patients with diabetes mellitus		A_1c<6.8%		A_1c≥6.8%		All patients with diabetes mellitus	A_1c<6.8%	A_1c≥6.8%
IPE dose (n=all patients, A_1c<6.8%, A_1c ≥6.8%)	All patients with diabetes mellitus		A_1c<6.8%		A_1c≥6.8%		All patients with diabetes mellitus	A_1c<6.8%	A_1c≥6.8%
IPE dose (n=all patients, A_1c<6.8%, A_1c ≥6.8%)	Baseline	End of treatment	Baseline	End of treatment	Baseline	End of treatment	Placebo-adjusted change from baseline, %, p
FPG, mg/dL
4 g/day	143	154	122	133	161	172	3.7	2.7	4.0
(n=160, 75, 85)	(38)	(53)	(23)	(37)	(39)	(59)	0.16	0.38	0.35
2 g/day	146	150	123	127	167	171	0.1	-2.8	2.6
(n=165, 79, 86)	(44)	(47)	(25)	(26)	(47)	(51)	0.99	0.36	0.54
Placebo	140	145	124	130	158	163
(n=158, 86, 72)	(35)	(39)	(25)	(30)	(37)	(41)
A _1c , %
4 g/day	6.9	7.2	6.2	6.5	7.6	7.9	1.4	1.3	1.7
(n=161, 76, 85)	(0.9)	(1.1)	(0.3)	(0.6)	(0.7)	(1.1)	0.14	0.27	0.29
2 g/day	7.0	7.2	6.2	6.3	7.8	8.0	0.1	-0.4	0.8
(n=167, 79, 88)	(1.1)	(1.2)	(0.4)	(0.5)	(0.9)	(1.1)	0.88	0.71	0.59
Placebo	6.8	7.0	6.2	6.4	7.5	7.7
(n=158, 86, 72)	(0.9)	(1.1)	(0.4)	(0.7)	(0.7)	(0.9)
Insulin, μIU/mL
4 g/day	20.6	18.5	20.0	19.3	21.2	17.7	-5.9	0.6	-13.4
(n=159, 76, 83)	(16.0)	(10.6)	(12.1)	(9.8)	(19.0)	(11.3)	0.43	0.95	0.26
2 g/day	18.9	19.1	16.8	17.4	21.1	20.7	-4.1	9.2	-17.8
(n=157, 79, 78)	(11.6)	(10.9)	(9.3)	(9.0)	(13.2)	(12.5)	0.59	0.32	0.14
Placebo	25.4	21.5	27.5	19.6	22.8	23.8
(n=156, 85, 71)	(38.2)	(18.9)	(48.2)	(13.9)	(20.6)	(23.5)
HOMA-IR
4 g/day	7.5	7.3	6.1	6.4	8.8	8.1	-1.4	3.0	-7.1
(n=158, 75, 83)	(7.5)	(6.2)	(3.8)	(3.7)	(9.5)	(7.7)	0.88	0.79	0.64
2 g/day	7.0	7.1	5.2	5.5	8.8	8.7	-8.8	6.0	-23.9
(n=157, 79, 78)	(5.0)	(4.8)	(3.4)	(3.1)	(5.6)	(5.6)	0.36	0.60	0.13
Placebo	9.6	7.9	9.7	6.4	9.4	9.6
(n=156, 85, 71)	(19.0)	(7.6)	(24.1)	(5.0)	(9.9)	(9.6)

Mean and standard deviation (SD) are reported for baseline and end-of-treatment values. Least-squares means are reported for the placebo-adjusted changes from baseline.
A_1c = glycosylated hemoglobin A_1c; FPG = fasting plasma glucose; HOMA-IR = homeostasis model assessment-estimated insulin resistance; IPE = icosapent ethyl.

Back to article page

ISSN: 1475-2840

Contact us

Submission enquiries: journalsubmissions@springernature.com